8-K filing — Bluejay Diagnostics, Inc. (BJDX)
Filed: 2026-10-13 AccNo: 0001213900-26-108779 Size: 258 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Bluejay Diagnostics Q2 EPS $(1.12) Up From $(5.64) YoY
Bluejay Diagnostics (NASDAQ:BJDX) reported quarterly losses of $(1.12) per share. This is a 80.14 percent increase over losses of $(5.64) per share from the same period last year.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bluejay Diagnostics Completes Establishment Of Manufacturing Site For Symphony Cartridges, Reaching Contractual Milestone As It Advances Toward Regulatory Submission And Potential Commercialization
Company Achieves Toray Contractual Milestone with Establishment of Manufacturing SiteACTON, MA / ACCESS Newswire / October 13, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"),
Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients
Bluejay Diagnostics released baseline data from its SYMON-II study, evaluating the IL-6 biomarker for mortality risk in sepsis patients.
Bluejay Diagnostics Reports SYMON-II Baseline Data Showing Diverse Critically Ill Sepsis Population And Meaningful Mortality Events Supporting IL-6 Evaluation For 28-Day Mortality Risk
SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Toward Regulatory SubmissionACTON, MA / ACCESS Newswire / October 6, 2026 / Bluejay Diagnostics, Inc.